CN102138990B - Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material - Google Patents
Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material Download PDFInfo
- Publication number
- CN102138990B CN102138990B CN201110066177A CN201110066177A CN102138990B CN 102138990 B CN102138990 B CN 102138990B CN 201110066177 A CN201110066177 A CN 201110066177A CN 201110066177 A CN201110066177 A CN 201110066177A CN 102138990 B CN102138990 B CN 102138990B
- Authority
- CN
- China
- Prior art keywords
- medicine
- preparation
- hepatitis
- chinese medicine
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 23
- 210000004185 liver Anatomy 0.000 title abstract description 16
- 239000000463 material Substances 0.000 title abstract description 5
- 231100000331 toxic Toxicity 0.000 title abstract 2
- 230000002588 toxic effect Effects 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 claims abstract description 16
- 206010008909 Chronic Hepatitis Diseases 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 231100000283 hepatitis Toxicity 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 8
- 231100000012 chronic liver injury Toxicity 0.000 claims description 6
- 231100000753 hepatic injury Toxicity 0.000 claims description 5
- 230000002085 persistent effect Effects 0.000 claims description 5
- 206010067125 Liver injury Diseases 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 33
- 206010019759 Hepatitis chronic persistent Diseases 0.000 abstract description 3
- 239000009636 Huang Qi Substances 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 206010019755 Hepatitis chronic active Diseases 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000171085 Polyporus umbellatus Species 0.000 abstract 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000233866 Fungi Species 0.000 description 30
- 240000001307 Myosotis scorpioides Species 0.000 description 30
- 230000001580 bacterial effect Effects 0.000 description 30
- 239000013641 positive control Substances 0.000 description 27
- 208000002672 hepatitis B Diseases 0.000 description 17
- 239000000796 flavoring agent Substances 0.000 description 15
- 235000019634 flavors Nutrition 0.000 description 15
- 238000001291 vacuum drying Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 206010019668 Hepatic fibrosis Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 108050009340 Endothelin Proteins 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000002734 Collagen Type VI Human genes 0.000 description 4
- 108010043741 Collagen Type VI Proteins 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 101710142246 External core antigen Proteins 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010023129 Jaundice cholestatic Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000001621 Mucoproteins Human genes 0.000 description 2
- 108010093825 Mucoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000005267 Obstructive Jaundice Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000035603 choleresis Effects 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method and new application of a traditional Chinese medicine composition for invigorating qi, nourishing the liver and clearing away heat and toxic material. The traditional Chinese medicine composition is prepared from the medicinal materials such as radix astragali, giant knotweed, polyporus umbellatus, bupleurum, angelica sinensis, oldenlandia diffusa, rhubarb, white peony root, aweto hypha powder and the like, and is used for treating chronic persistent hepatitis and chronic active hepatitis.
Description
The present invention is for dividing an application, and the original bill application number is 200710119345.9, and the original bill applying date is on July 20th, 2007, and the original bill name is called a kind of QI invigorating nourishing the liver, Chinese medicine composition of heat-clearing and toxic substances removing and preparation method thereof.
Technical field
The present invention relates to a kind of QI invigorating nourishing the liver, Chinese medicine composition of heat-clearing and toxic substances removing and preparation method thereof relates in particular to a kind of chronic persistent active type hepatitis card that is used for and sees deficiency of both QI and YIN, and damp and hot unclear Chinese medicine composition that waits and preparation method thereof belongs to technical field of Chinese medicines.
Background technology
Before nineteen ninety-five be divided into chronic hepatitis B: two types of chronic persistent hepatitis (CPH) and chronic active type hepatitis ies (CAH).Nineteen ninety-five the 5th national infectious disease meeting, hepatopathy expert revises the viral hepatitis scheme of preventing and treating.Three types of, moderate slight, severes to no matter being that chronic hepatitis diagnosis that B-mode, third type, fourth type or new virus cause is all divided.
Hepatitis B (being called for short hepatitis B or hepatitis B) is a kind of infectious disease that China's current popular is the most extensive, harm is the most serious.Sanitary condition is relatively poor, the level of economic development is low is the popular basis of this disease.Clinical manifestation: weak, loss of appetite, detest oil, nausea,vomiting,diarrhea, abdominal distention, heating, jaundice, the concealment of half people onset is arranged; Find in the health check-up; Abnormal liver function; Serum and hepatitis B surface antigen, hepatitis B virus DNA, hepatitis B virus immune globulin M, deoxyribonucleic acid polymerase is all positive.
The chronic viral hepatitis B onset is slow, and the course of disease is long, and the state of an illness is changeable repeatedly, and delay is difficult.The treatment chronic hepatitis, doctor trained in Western medicine adopts interferon and ucleotides antiviral drugs more, but aspects such as the safety of this type of medicine late result, medicine and drug resistance all are difficult to guarantee.The traditional Chinese medical science thinks that the reason that chronic hepatitis B produces is that the human righteousness is not solid, invades in the epidemic disease caused by damp-heat pathogen poison, is reluctant to leave and does not go, and causes liver,spleen,kidney impaired, thereby forms the situation of vital QI being weakened and pathogen being violent.Wherein, the paathogenic factor that produces in the damp and hot and course of disease is blood stasis one by one, is the key factor of hepatitis chronicity.According to the degree of what and internal organs deficiency and excess of damp and hot, blood stasis, different pathological changes, and uses different method of treatment (a kind of method of treatment is main, and multiple method of treatment is share), selects for use different prescriptions to treat.The Chinese medicine chronic hepatitis B has definite curative effect, especially at anti-hepatic fibrosis, prevent the hepatitis chronicity, regulate immunity, aspects such as enzyme fall in hepatoprotective, curative effect is better.
Summary of the invention
The invention provides a kind of QI invigorating nourishing the liver, the pharmaceutical composition of heat-clearing and toxic substances removing is mainly used in the treatment of chronic persistent, active type hepatitis.
Another object of the present invention has provided this preparation of drug combination method.
Chinese medicine composition provided by the invention is prepared from the following weight proportion raw material:
Pharmaceutical composition of the present invention is preferably:
Pharmaceutical composition of the present invention is preferably:
Pharmaceutical composition of the present invention is preferably:
Pharmaceutical composition of the present invention also passes through scientific preparation process; Be prepared into various preparations such as the capsule that is fit to clinical practice, tablet, granule, oral liquid, soft capsule, drop pill, dispersible tablet, effervescent, slow releasing preparation; Not only overcome the shortcoming of Chinese medicine compound preparation, and significantly improved curative effect of medication.
Preparation of drug combination method of the present invention is:
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 1～3 time; Each 1～3 hour, collecting decoction was concentrated into relative density 1.20-1.40 (60 ℃), vacuum drying; Pulverize; With the Chinese caterpillar fungus bacterial filament powder mix homogeneously, add the various preparations that suitable adjuvant is prepared into clinical practice, comprise capsule, tablet, granule, oral liquid, soft capsule, drop pill, dispersible tablet, effervescent, slow releasing preparation etc.
The preferred manufacturing procedure of pharmaceutical composition of the present invention is:
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Radix Astragali invigorating QI to consolidate the body surface resistance in the pharmaceutical composition of the present invention, promoting urination to remove dampness, the Rhizoma Polygoni Cuspidati heat-clearing and toxic substances removing, the dampness removing jaundice eliminating is monarch drug altogether.Polyporus eliminating dampness by diuresis spleen invigorating, Radix Paeoniae Alba easing the affected liver, relieving spasm to stop pain, Chinese angelica blood supplementing is invigorated blood circulation, pain relieving, more than each medicine be ministerial drug altogether.The Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI, Herba Hedyotidis Diffusae heat-clearing and toxic substances removing, diuresis, the Radix Et Rhizoma Rhei heat-clearing and toxic substances removing, the Cordyceps invigorating the lung and the kidney, more than each medicine be adjuvant drug altogether.We's QI invigorating nourishing the liver, heat-clearing and toxic substances removing is used for deficiency of both QI and YIN, damp and hot card clearly, chronic persistent active type hepatitis has above-mentioned disease person.Pharmaceutical composition of the present invention has embodied the Chinese traditional treatment chronic hepatitis B and has consolidated the characteristics of taking stopgap measures, and not only Liver and kidney QI of the spleen and stomach blood obtains tonification, and damp and hot poison is able in body, remove.
Beneficial effect:
Test Example one
1. materials and methods
1.1 laboratory animal: kunming mice, cleaning level, male and female dual-purpose, sub-cage rearing, body weight 18-23g, totally 60.
1.2 divide into groups: 120 kunming mices are divided into 8 groups at random, and 15 every group, the A group is the normal control group; The B group is model control group; C, D, E organize positive control drug (commercially available liver DAKANG PIAN) treatment group; F, G, H group are the medicine composite for curing group of the present invention according to embodiment 1 preparation.
1.3 modeling method: adopt the method for bacillus calmette-guerin vaccine and lipopolysaccharide associating to set up the immunologic liver injury mouse model.After each treated animal adaptability is fed 3d, except that the normal control group, 1 tail vein injection bacillus calmette-guerin vaccine 5 * 10 of every mice
7Individual viable bacteria, 12d intravenous injection lipopolysaccharide 7.5 μ g/ Mus are put to death behind 16h and draw materials after injection of BCG, and the normal control group is all injected the equivalent normal saline with same procedure 2 times.
1.4 administration and processing: played the beginning gastric infusion, 1 time/d in first day of the intravenous injection bacillus calmette-guerin vaccine.Normal control group and model control group: normal saline is irritated stomach, irritates the medication capacity of stomach amount with medication therapy groups; Positive control medicine treatment group: the large, medium and small dosage of liver DAKANG PIAN medicine (dose of quite being grown up 10,20,30 times) administration; Medication therapy groups of the present invention: according to the large, medium and small dosage of medicine of the present invention of embodiment 1 preparation (dose of quite being grown up 10,20,30 times) administration.Normal control group 16h behind the 12d injecting normal saline, the eyeball rear vein beard is got blood, and puts to death animal and get the hepatic tissue censorship; All the other 3 groups 16h behind the intravenous injection lipopolysaccharide, the eyeball rear vein beard is got blood, and puts to death animal and get the hepatic tissue censorship.
1.5 observation index and detection method: 1. detect glutamate pyruvate transaminase (ALT): adopt chemical colorimetry to measure.2. endogenous nitric oxide (NO) is measured: adopt radioimmunology, cut open and get the 0.5g liver and process 10% liver tissue homogenate, and under 4 ℃ of conditions, 3000 commentaries on classics/min, centrifugal 10min gets supernatant.3. Endothelin (ET) detects: adopt and put the method for exempting from and directly measure blood plasma ET concentration.4. pathological observation: after continuing to irritate stomach 12d, all the eyeball of mouse blood sampling is put to death, and cuts open immediately and gets hepatic tissue; Gross examination of skeletal muscle liver quality, color and luster, have or not tuberosity, hemorrhage etc., and get the same position of liver organization and do the pathology section, fix with 10% formalin; Conventional dehydration; Specimens paraffin embedding slices, HE dyeing, light microscopic is observed the hepatic pathology morphological change down.
2. result
Table 1 is respectively organized the situation of change of mice pathology integration
The situation of change that table 2 is respectively organized Serum ALT, ET, NO compares
* compare * P＜0.05, * * P＜0.01 with model group; △ and positive controls compare, △ P＜0.05.
Can find out that from above result medicine of the present invention has significance to improve to ALT, ET, NO content in the hepatic injury mice serum, with the positive control medicine significant difference is arranged relatively.
2, to the protective effect of chronic hepatic injury
Rat skin lower injection 10%5ml/kg carbon tetrachloride oil solution, 2 times weekly, injected continuously 3 months, cause carbon tetrachloride chronic hepatic injury animal model, observe the protective effect of medicine of the present invention to the damage liver.
Table 3 medicine of the present invention is to the protective effect of chronic hepatic injury rat (X ± SD)
* compare * P＜0.05, * * P＜0.01 with model group; △ and positive controls compare, △ P＜0.05.
Experimental result shows, compares with model group, and the SGPT of the large, medium and small dose groups of positive control medicine and medicine of the present invention, SGOT content obviously reduce; The A/G value of the large and small dose groups of positive control medicine and the large, medium and small dose groups of medicine of the present invention obviously raises; Hydroxyproline content obviously reduces in the large, medium and small dose groups serum of medicine of the present invention, hydroxyproline content no significant difference in the large, medium and small dose groups serum of positive control medicine.Above result shows that medicine of the present invention is superior to the positive control medicine to the protective effect of chronic hepatic injury rat.
3, function of gallbladder promoting, jaundice eliminating effect
3.1 choleretic effect
The choleretic effect of table 4 drug regimen of the present invention (X ± SD)
* compare * P＜0.05 * * P＜0.01 with the normal control group; △ and positive controls compare, △ P＜0.05.
Experimental result shows, compares the bile amount showed increased of the big or middle dose groups of positive control medicine, and the bile amount showed increased of the large, medium and small dose groups of medicine of the present invention, positive control medicine small dose group no significant difference (P＞0.05) with normal group; Medicine of the present invention and positive control medicine compare, and the mice choleresis has significance to increase.
3.2 jaundice eliminating effect
Table 5 pharmaceutical composition of the present invention is to the protective effect of obstructive jaundice mice (X ± SD)
* compare * P＜0.05 * * P＜0.01 with the normal control group; △ and positive controls compare, △ P＜0.05.
Experimental result shows, compares with normal group, and SGPT, SB content obviously raise in the serum of model group; Compare with model group, the big or middle dose groups of positive control medicine and medicine of the present invention and the SGPT content of medicine small dose group of the present invention obviously reduce; The SB content of the big or middle dose groups of medicine of the present invention obviously reduces.Above result of the test shows that medicine of the present invention significantly is superior to the positive control medicine to the protective effect of obstructive jaundice mice.
3.3 to of the influence of engulfing clean up ability of mice reticuloendothelial system to inertia carbon granules in the blood flow
Table 6 pharmaceutical composition of the present invention is to the influence of macrophage phagocytic function (X ± SD)
* compare * P＜0.05 * * P＜0.01 with the normal control group; △ and positive controls compare, △ P＜0.05.
Experimental result shows, compares with normal group, and the K value of model group obviously reduces (P＜0.01).Compare with model group, the medicine small dose group K value big or middle dose groups of positive control medicine and medicine of the present invention and of the present invention obviously increases (P＜0.01), and the low dose of effect not obvious (P＞0.05) of positive control medicine.Medicine of the present invention has significance to improve the phagocytic function of macrophage than the positive control medicine.
Above results of pharmacodynamic test shows that medicine of the present invention has significance to reduce to intravital ET of immunologic liver injury mice and ON level, and anti-hepatic fibrosis can effectively be treated chronic hepatitis.The chronic hepatic injury rat there is remarkable protective effect, effectively improves the mice choleresis, obstructive type icteric hepatic injury mice is had protective effect, engulf the clean up ability of mice reticuloendothelial system to inertia carbon granules in the blood flow is significantly increased.
Test Example two
1.1 physical data
Selection is diagnosed as being in hospital of chronic hepatitis B and part clinic case 200 examples are classified the object of observation as, is divided into treatment group and matched group at random.The concrete distribution like following table:
Table 7 clinic case grouping basic condition
Can find out that from last table treatment group and matched group do not have significant difference on each item basic index distributes.
1.2 diagnostic criteria
Unite the diagnostic criteria of " viral hepatitis is prevented and treated scheme " of revising and relevant chronic viral hepatitis B and formulate with reference in JIUYUE, 2000 China medical association infectious disease and parasitic disease credit meeting, the Xi'an meeting of hepatopathy association.Chinese medical discrimination standard and symptom and sign quantitative criteria are formulated with reference to " new Chinese medicine clinical research guideline ".
1.3 the standard of including in
1. meet hepatitis B Western medicine diagnose standard person.
2. the age between 18～65 years old, male or female.
3. the course of disease is more than half a year.
1.4 exclusion standard
1. merge HAV, HCV,, HDV, HFV the infected.
2. the hepatitis gravis due to the HBV, decompensated liver cirrhosis and liver cancer patient.
3. long-term alcoholic, psychotic and anemia of pregnant woman.
4. be associated with serious protopathy person such as cardiovascular and cerebrovascular vessel, breathing, urinary system and hemopoietic system.
5. the patient of under-18s or over-65s.
2 Therapeutic Method
2.1 treatment group
According to the pharmaceutical composition of the present invention of embodiment 1 preparation, dose, one time 3～4,3 times on the one.
2.2 matched group
Commercially available liver DAKANG PIAN, dose, one time 8～10,3 times on the one.
Be 6 courses of treatment observing time, and wherein some cases can extend the period of treatment to 1 year.Treatment was followed up a case by regular visits to 6 months after finishing.
Viewing duration is forbidden adding and is used immunologic function and the influential other medicines of virus replication. like interferon, thymus skin, virazole, acyclovir etc.
3 results
3.1 observation index
Observe hypochondriac pain, appetite, weak, abdominal distention, yellow cellulitis, hepatosplenomegaly, tongue fur, pulse condition etc. adopt the integration method record.Liver function index: alanine aminotransferase (ALT), aspartate amino transferase (AST), glutamyl transpeptidase (GGT), alkali phosphatase (ALP), serum bilirubin (TB), albumin (A), globulin (G); Nosetiology index (HBsAg, anti-HBs; HBeAg, anti-HBe, anti-HBe, the swimming of egg
white appliances; Hepatic fibrosis index: hyaluronic acid (HA), layer mucoprotein (LN) and IV Collagen Type VI.
3.2 comprehensive therapeutic effect evaluation criteria
Reply the normal again .HBV-DNA of (produce effects): ALT fully, HBeAg, HBsAg are all cloudy to be changeed; Part is replied normal again .HBV-DNA of (effectively): ALT and the cloudy commentaries on classics of HBeAg, but HBsAg is still positive; No response (invalid): do not reach These parameters person.
3.4 general curative effect analysis
In the treatment, the treatment after do not see any untoward reaction.
(1) symptom and sign: the treatment group respectively organize symptom all have in various degree improve P＜0.01; Weak, the yellow cellulitis of matched group, abdominal distention also have certain improvement, P＜0.05; Compare with matched group, pharmaceutical composition of the present invention can obviously improve patient's hypochondriac pain, poor appetite symptom .P＜0.05 and see table 1).
Before and after table 8 treatment symptom, sign integration change (x ± s, n=100)
Compare * * P＜0.01 before and after each group treatment; * P＜0.05, treatment group and matched group be
P＜0.05 relatively.
(2) comprehensive therapeutic effect:
Table 9 Comprehensive Treatment situation
Treatment group and matched group be
P＜0.05 relatively.
Can find out that from above result medicine total effective rate of the present invention is significantly higher than the positive control medicine on the curative effect of treatment chronic hepatitis B.
3.5 liver function changes
Serum aminotransferase activity is for diagnosis of viral hepatitis.The understanding hepatocyte decreases the degree of going has certain reference value. and the transaminase often has rising when the hepatitis B activity.Medicine of the present invention and positive control medicine are to the change of chronic hepatitis B patient liver function, and the result sees the following form.
Liver function change before and after table 10 treatment (x ± s, n=100)
Annotate: each group is treated front and back relatively, * P＜0.05
Can find out that from last table pharmaceutical composition of the present invention and positive control medicine have significance to improve to the chronic hepatitis B patient liver function, the effect of medicine of the present invention is superior to the positive control medicine.
3.6 hepatic fibrosis index changes
LN is an extracellular matrix glycoprotein, is the main component of basement membrane, with fibrosis, portal hypertension degree good dependency is arranged; HA is the important component of extracellular matrix. sensitivity, specificity to the diagnosis liver cirrhosis are higher; Synchronous detecting blood.Clear HA, LN, IV Collagen Type VI can react the degree of hepatic fibrosis basically.The result sees the following form:
Hepatic fibrosis index variation before and after table 11 treatment (x ± s, n=100)
Annotate: each group treatment front and back relatively; * P＜0.05;
P＜0.05 is compared with positive controls in * P＜0.01.
Observed result shows: after drug group of the present invention and the treatment of positive controls case. hyaluronic acid (HA), layer mucoprotein (LN), IV Collagen Type VI hepatic fibrosis indexs such as (IVC) all have improvement in various degree.The serum HA that two groups of patients raise, LN, IV Collagen Type VI all, there were significant differences before the treatment.The positive control medicine that is superior to evident in efficacy of medicine of the present invention.
Can find out that from above clinical test results medicine of the present invention has better curative effect to the treatment of chronic hepatitis B, and does not have clinical adverse.
Following further explain technical scheme of the present invention, but therefore the present invention does not receive any restriction.
Specific embodiment
Embodiment 1
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 1～3 time; Each 1～3 hour, collecting decoction was concentrated into relative density 1.20-1.40 (60 ℃), vacuum drying; Pulverize; With the Chinese caterpillar fungus bacterial filament powder mix homogeneously, add the various preparations that suitable adjuvant is prepared into clinical practice, comprise capsule, tablet, granule, oral liquid, soft capsule, drop pill, dispersible tablet, effervescent, slow releasing preparation etc.
Embodiment 2
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 3
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 4
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder,
is inferior in decocte with water; Each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying; Pulverize; With the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulate, promptly get.
Embodiment 5
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction concentrated
To relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, with the Chinese caterpillar fungus bacterial filament powder mix homogeneously,
Incapsulate, promptly get.
Embodiment 6
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 7
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 8
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 9
More than nine flavors, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying is pulverized, and with the Chinese caterpillar fungus bacterial filament powder mix homogeneously, incapsulates, and promptly gets.
Embodiment 10
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times; Each 2 hours, collecting decoction was concentrated into relative density 1.36-1.38 (60 ℃), vacuum drying; Pulverize,, granulate with the Chinese caterpillar fungus bacterial filament powder mix homogeneously; Drying, granulate adds a small amount of magnesium stearate; Mixing,
clothing promptly gets.
Embodiment 11
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours; Collecting decoction is concentrated into relative density 1.36-1.38 (60 ℃), and vacuum drying is pulverized, with the Chinese caterpillar fungus bacterial filament powder mix homogeneously; Fine drug powder and fused Macrogol 4000 are even according to 3: 7 mixed, 70～80 ℃ of insulations, at the uniform velocity, splash in the refrigerative liquid paraffin; Drop is liquid coolant to the greatest extent, and drying promptly gets drop pill.
Embodiment 12
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours; Collecting decoction is concentrated into relative density 1.36-1.38 (60 ℃), and vacuum drying is pulverized; With the Chinese caterpillar fungus bacterial filament powder mix homogeneously, fine drug powder and vegetable oil add an amount of suspending agent according to 1: 1 mixed; Mixing is pressed into soft capsule, promptly gets.
Embodiment 13
More than nine the flavor, except that Chinese caterpillar fungus bacterial filament powder, decocte with water 2 times, each 2 hours; Collecting decoction is concentrated into relative density 1.36-1.38 (60 ℃), adds ethanol and makes and contain alcohol amount and reach 65%, leaves standstill 24h; Get supernatant and reclaim ethanol, vacuum drying is pulverized; With Chinese caterpillar fungus bacterial filament powder and appropriate amount of starch mix homogeneously, incapsulate, promptly get.
Claims (7)
1. Chinese medicine preparation of drug combination method of treating chronic persistent, active type hepatitis, it is characterized in that: it is to be prepared by following raw materials by weight proportions:
2. Chinese medicine preparation of drug combination method of treating chronic persistent, active type hepatitis, it is characterized in that: it is to be prepared by following raw materials by weight proportions:
3. the method for claim 1, it is characterized in that: the weight proportion of said crude drug is:
4. according to the described method of claim 1, it is characterized in that said Chinese medicine pharmaceutical composition is to be prepared from following raw materials by weight proportions:
5. treat the application in the chronic hepatic injury medicine like the medicine of the arbitrary said method preparation of claim 1-4 in preparation.
6. treat the application in the chronic hepatitis medicine like the medicine of the arbitrary said method preparation of claim 1-4 in preparation.
7. treat the application in the obstructive type icteric liver injury medicament like the medicine of the arbitrary said method preparation of claim 1-4 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110066177A CN102138990B (en) | 2007-07-20 | 2007-07-20 | Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110066177A CN102138990B (en) | 2007-07-20 | 2007-07-20 | Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101193459A Division CN101099780B (en) | 2007-07-20 | 2007-07-20 | Traditional Chinese medicinal composition for qi-benefiting, liver-nourishing, heat-clearing and antitoxic and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102138990A CN102138990A (en) | 2011-08-03 |
| CN102138990B true CN102138990B (en) | 2012-10-03 |
Family
ID=44406932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110066177A Active CN102138990B (en) | 2007-07-20 | 2007-07-20 | Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102138990B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727926A (en) * | 2016-12-12 | 2017-05-31 | 深圳利孚生物科技有限公司 | The medicine and preparation method of anti-hepatic fibrosis and treatment cirrhosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
-
2007
- 2007-07-20 CN CN201110066177A patent/CN102138990B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113779A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Anti- hepatitis B preparation |
Non-Patent Citations (2)
| Title |
|---|
| 江红兵等.中医治疗慢性乙型肝炎的方法与用药概况.《山西中医》.2002,第18卷(第05期), * |
| 罗国钧.慢性肝炎的中医及中西医结合治疗进展.《山西中医》.1994,第10卷(第03期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727926A (en) * | 2016-12-12 | 2017-05-31 | 深圳利孚生物科技有限公司 | The medicine and preparation method of anti-hepatic fibrosis and treatment cirrhosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102138990A (en) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102755594B (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN102283867B (en) | Traditional Chinese medicine composition for treating cancer | |
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN101332284A (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| CN104644915A (en) | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition | |
| CN101934052A (en) | Medicament for treating facial chloasma and preparation method thereof | |
| CN1994455A (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN101417029A (en) | Medicine composition for treating cholecystitis | |
| CN102885928A (en) | Chinese medicinal injection for treating jaundice and preparation method thereof | |
| CN1137696C (en) | Medicine for treating hepatitis B and rheumatoid diseases | |
| CN101036741B (en) | Medicine for treating cancer and preparing method therefor | |
| CN102349993B (en) | Bupleurum tenue granules and preparation method thereof | |
| CN102138990B (en) | Preparation method and new application of traditional Chinese medicine composition for invigorating qi, nourishing liver and clearing away heat and toxic material | |
| CN101099780B (en) | Traditional Chinese medicinal composition for qi-benefiting, liver-nourishing, heat-clearing and antitoxic and preparation method thereof | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN101062374B (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN102366477A (en) | Pure traditional Chinese medicine preparation for treating hepatitis | |
| CN101244186A (en) | Medicine preparation for treating hepatitis B, and method of preparing the same | |
| CN101485753B (en) | Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN102743477B (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof | |
| CN110575521A (en) | A traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensated liver cirrhosis and its use | |
| CN117982557B (en) | Use of fermented black bean ginger or its extract and composition | |
| CN103393814A (en) | Traditional Chinese medicine composition capable of treating abnormal liver functions | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |